Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G250 Peptide Vaccine with IL-2 in Resected Renal Cell Carcinoma
NCT00203866Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Oct 2003
- Primary completion
- Mar 2007
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised trial of G250 peptide in renal cell carcinoma (RCC), sponsored by University of Chicago. Primary endpoint: Specific CTL response as assessed by ELISPOT. Started Oct 2003; status: terminated.
02
Drugs
G250 peptide
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00203866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203866.